CN110913884B - 抑制dna依赖蛋白激酶催化亚基的药物 - Google Patents

抑制dna依赖蛋白激酶催化亚基的药物 Download PDF

Info

Publication number
CN110913884B
CN110913884B CN201880046593.1A CN201880046593A CN110913884B CN 110913884 B CN110913884 B CN 110913884B CN 201880046593 A CN201880046593 A CN 201880046593A CN 110913884 B CN110913884 B CN 110913884B
Authority
CN
China
Prior art keywords
endostatin
cells
dna
etoposide
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880046593.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110913884A (zh
Inventor
罗永章
贾琳
常国栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CN110913884A publication Critical patent/CN110913884A/zh
Application granted granted Critical
Publication of CN110913884B publication Critical patent/CN110913884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880046593.1A 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物 Active CN110913884B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710638033 2017-07-30
CN2017106380332 2017-07-30
CN2017107339000 2017-08-24
CN201710733900 2017-08-24
PCT/CN2018/097609 WO2019024814A1 (zh) 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物

Publications (2)

Publication Number Publication Date
CN110913884A CN110913884A (zh) 2020-03-24
CN110913884B true CN110913884B (zh) 2023-06-06

Family

ID=65233426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880046593.1A Active CN110913884B (zh) 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物

Country Status (7)

Country Link
US (2) US20200237796A1 (enExample)
EP (1) EP3662922B1 (enExample)
JP (1) JP7492687B2 (enExample)
CN (1) CN110913884B (enExample)
AU (1) AU2018310410B2 (enExample)
CA (1) CA3103035A1 (enExample)
WO (1) WO2019024814A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087785A2 (en) 1998-06-15 2001-04-04 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
ES2288318T3 (es) 1998-06-30 2008-01-01 Sloan-Kettering Institute For Cancer Research Uso de dna-pk.
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
WO2013034116A1 (zh) 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NCI-H520 [H520]ATCC HTB-182(TM) Homo sapiens lung squamous c;匿名;《Https://www.lgcstandards-atcc.org/Products/All/HTB-182.aspx？geo_country=nl#characteristics》;20160101;全文 *
The radiosensitization effects of Endostar on human lung squamous cancer cells H-520;Zhen Y You等;《Cancer Cell International》;20100524;1-10 *

Also Published As

Publication number Publication date
EP3662922A4 (en) 2021-04-07
US20200237796A1 (en) 2020-07-30
AU2018310410B2 (en) 2024-11-14
AU2018310410A1 (en) 2020-03-12
CA3103035A1 (en) 2019-02-07
JP7492687B2 (ja) 2024-05-30
EP3662922B1 (en) 2025-03-05
JP2020528457A (ja) 2020-09-24
US20240165140A1 (en) 2024-05-23
CN110913884A (zh) 2020-03-24
WO2019024814A1 (zh) 2019-02-07
EP3662922A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
Zhang et al. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
Gordon‐Weeks et al. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice
Kuchnio et al. The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts
ES2928111T3 (es) Inhibición de la señalización AXL en terapia antimetastásica
Folkman Endogenous angiogenesis inhibitors
Sun et al. Identification of PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) as an essential gene for colorectal cancer (CRCs) cells
Kurozumi et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61
JP2020010701A (ja) インターロイキン−４受容体結合融合タンパク質及びその使用
Lee et al. Tissue transglutaminase activates cancer-associated fibroblasts and contributes to gemcitabine resistance in pancreatic cancer
WO2016061231A1 (en) Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
Li et al. Biliverdin protects against cerebral ischemia/reperfusion injury by regulating the miR-27a-3p/Rgs1 axis
Michaelsen et al. Single agent‐and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells
JP2022104932A (ja) ｄｓＲＮＡを標的化するためのキメラタンパク質
WO2021162120A1 (ja) 相同組換え活性を測定可能な核酸構築物及びその利用
CN110913884B (zh) 抑制dna依赖蛋白激酶催化亚基的药物
Pruller et al. A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
Yao et al. Fanconi anemia pathway—the way of DNA interstrand cross-link repair
Yaghoubi et al. Anticancer activity of Pseudomonas aeruginosa derived peptide with iRGD in colon cancer therapy
WO2009014702A2 (en) Cd74 for use in the treatment of cancer and liver toxicity
Luo et al. Genetically Engineered Biomimetic Nanoparticles for Synergistic Activation of Glioma-Associated Macrophages against Glioblastoma
Xiao et al. Synergistic inhibition of APE1 redox activity and ATM activation sensitizes osteosarcoma cells to ionizing radiation by inducing ferroptosis
Zhang Antisense Therapy in Mouse Models of Histone H3. 3k27m Diffuse Midline Glioma Inhibits Tumor Growth, Promotes Neural and Glial Differentiation
US20170079966A1 (en) Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
Greene et al. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells 2023, 12, 581
WO2024245445A1 (zh) Malt1肿瘤抑制剂、含有其的药物及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant